Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information

Xaliproden hydrochloride

EU orphan designation number: EU/3/00/015
Active ingredient: Xaliproden hydrochloride
Indication: Treatment of amyotrophic lateral sclerosis
Sponsor: Sanofi-Aventis
174 avenue de France, F-75013 Paris, France

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/01/2001 Orphan designation EMEA/OD/029/00 (2001)109 of 17/01/2001
02/06/2006 Change of name and/or address of sponsor
03/05/2010 Removal of orphan designation from Community Register